CD39 transforming cancer therapy by modulating tumor microenvironment
Cancer Letters · 2024-08 · 597 · 217072
DOI: 10.1016/j.canlet.2024.217072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Suling Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Apyrase. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: xusuling@nbu.edu.cn.
- Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: myhuwm@163.com.
- Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: jiangliu0319@163.com.
- Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, China. Electronic address: wqq@zju.edu.cn.
- Department of Medicine, Sanford Stem Cell Institute, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: wma@health.ucsd.edu.
Zitieren
APA
Xu, S., Ma, Y., Jiang, X., Wang, Q., & Ma, W. (2024). CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Letters, 597, 217072. https://doi.org/10.1016/j.canlet.2024.217072
Vancouver
Xu S, Ma Y, Jiang X, Wang Q, Ma W. CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Letters. 2024;597:217072. doi:10.1016/j.canlet.2024.217072
BibTeX
@article{Xu2024,
author = {Xu, Suling and Ma, Yuhan and Jiang, Xinyu and Wang, Qingqing and Ma, Wenxue},
title = {CD39 transforming cancer therapy by modulating tumor microenvironment},
journal = {Cancer Letters},
year = {2024},
volume = {597},
pages = {217072},
doi = {10.1016/j.canlet.2024.217072}
}
EUVIMED